Moderna released an update ahead of the J.P. Morgan Healthcare Conference, raising its 2025 revenue expectation to $1.9 billion and announcing a significant cut in operating expenses to between $5.0 billion and $5.2 billion. The positive financial outlook caused the stock to surge by over 15% to $39.12.
- The company reported a strong cash position of $8.1 billion.
- Moderna projects 2026 revenue growth of up to 10%.
- Pipeline progress includes potential approvals for flu vaccines in 2026.